ClinicalTrials.gg
Active, not recruitingNCT07076121Updated Jun 3, 2026

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

A Phase 2/3 interventional study of Navlimetostat and Gemcitabine in Pancreatic Ductal Adenocarcinoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 269 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb — 3 open to participants now, 5 under way, 1 of them phase 3. Pancreatic Neoplasms · Bristol-Myers Squibb.

Planned enrollment
4th of 23
470 · median 105
Started
2025
with 1 other
Phase 2/3
Only one
of the 27
Registered
25th of 27
by date

Among the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2/3, and was the 25th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pancreatic Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma

Keywords

  • PRMT5
  • MTAP
  • MRTX1719
  • MountainTAP
  • Pancreatic cancer
  • PDAC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC).
  • Evidence of homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss detected in tumor tissue.
  • Metastatic disease with at least 1 as per version v1.1 (RECIST v1.1).
  • Participants must not have received any systemic anticancer treatments in the metastatic setting.
  • If clinically indicated and as per investigator discretion, participants may receive up to 1 cycle of Nab-paclitaxel/Gemcitabine (nab-p/gem) in the metastatic setting and must have not progressed or required discontinuation due to intolerable toxicity.
  • Initial cycle of nab-p/gem administered in the metastatic setting must have been completed prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Concurrent (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to screening.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
470 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Navlimetostat · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Arm B

    Drug: Navlimetostat · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Placebo comparator
    Arm C

    Drug: Gemcitabine · Drug: Nab-paclitaxel · Drug: Placebo

  • Placebo comparator
    Arm D

    Drug: Gemcitabine · Drug: Nab-paclitaxel · Drug: Placebo

  • Experimental
    Arm E

    Drug: Navlimetostat · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Placebo comparator
    Arm F

    Drug: Gemcitabine · Drug: Nab-paclitaxel · Drug: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986504, MRTX1719

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Abraxane

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)

    Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first)

    Time frame: Up to 3 years after last participant is randomized

  2. Overall Survival (OS)

    Defined as the time from the randomization date to the date of death from any cause

    Time frame: Up to 3 years after last participant is randomized

Secondary outcomes

  1. Objective Response (OR) as assessed by RECIST v1.1

    Time frame: Up to 3 years after last participant is randomized

  2. Duration of Response (DOR) as assessed by RECIST v1.1

    Defined as the time between the date of the first documentation of objective tumor response (complete response (CR) or partial response (PR)) and the date of disease progression or to death from any cause (whichever occurs first)

    Time frame: Up to 3 years after last participant is randomized

  3. Time to Objective Response (TTOR) as assessed by RECIST v1.1

    Defined as the time between randomization to the date of the first documentation of objective tumor response

    Time frame: Up to 3 years after last participant is randomized

  4. Disease control as assessed by RECIST v1.1

    Defined as the best overall response (BOR) of confirmed CR, PR, or stable disease (SD)

    Time frame: Up to 3 years after last participant is randomized

  5. Number of participants with treatment-related adverse events (TRAEs)

    Time frame: Up to 28 days after the last drug administration

  6. Number of participants with all-cause treatment-emergent adverse events (TEAEs)

    Time frame: Up to 28 days after the last drug administration

  7. Number of participants with treatment-emergent serious adverse events (TESAEs)

    Time frame: Up to 28 days after the last drug administration

  8. Number of participants with TEAEs leading to dose interruption, reduction, or discontinuation

    Time frame: Up to 28 days after the last drug administration

  9. Number of participants with laboratory abnormalities

    Time frame: Up to 28 days after the last drug administration

  10. PFS as assessed by RECIST v1.1

    Time frame: Up to 3 years after last participant is randomized

07

Study locations

269 sites

Showing the first 100 of 269 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for May 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 21, 2025
StartActual
Oct 23, 2025
Primary completionEst.
May 3, 2029
CompletionEst.
May 3, 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076121
Responsible party
Sponsor
First posted
Jul 21, 2025
Start date
Oct 23, 2025
Primary completion
May 3, 2029 (estimated)
Completion
May 3, 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion